In the North American biotech space, you hear a lot of ‘promise’ from companies and their teams. Lots of ‘we’re going to take this to
PINK is accelerating toward the commercialisation of the OTIS platform. It has already received a $7.4 million grant (non-dilutive capital) from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the ATLAS AI Project.
As a student of economics, I believe the stock market at times acts like an old-style ‘beauty contest’. This theory is not new but has
Investing your money in health or medical companies is difficult. The complexity of the science often deters investors from allocating a portion of their portfolio
The new economy is digital. It’s in the trillions, so increasing digitization of the world has led to an increased risk that some parts of
For the last eight months, the Covid-19 virus has been the centre of attention in the media, the markets, and the medical field. Collectively, countries,
Aytu BioScience (AYTU.Q) signed a distribution agreement with Apollo Med Innovations to distribute their COVID-19 IgG/IgM Rapid Test Cassette to Apollo’s network of 1,000 doctor’s
Cognetivity Neurosciences’ (CGN.C) latest scientific publication touts their Integrated Cognitive Assessment (ICA) tool as a weapon for detecting and monitoring cognitive impairment associated with neurodegenerative
Here’s a simple and effective investment strategy: invest in companies that sell
products with growing inelastic demand.
Abbott Laboratories (ABT.NYSE) announced their FreeStyle Libre system, a sensor-based glucose monitoring tech, is now being used in hospitals setting during the COVID-19 pandemic. This
Respect where it’s due, I haven’t been to an investor conference in a long time where I came away interested in most of what I saw, let alone *everything* I saw, but this year’s Gravitas Securities Growth Conference lineup absolutely hit it out of the park. The GSGC isn’t the biggest show around, but they know how to turn out the playahs, and the only way you keep big money showing up is to be a little bit picky with what you offer them. Don’t waste anyone’s time and they’ll know it’s cool to return.
Abbott Laboratories (ABT.NYSE) received Food and Drug Administration (FDA) approval for a new alternative surgical technique for Abbott’s HeartMate 3 heart pump that would allow
Varian Medical Systems (VAR.NYSE) announced that the South Florida Proton Therapy Institute (SFPTI) has treated its first patient using the Varian ProBeam Compact single-room proton
Cognetivity Neurosciences (CGN.C) has reached the threshold of participants in their clinical evaluation study of its integrated cognitive assessment (ICA) platform for dementia sufferers to
Australia is a member of the assorted collection of countries with aging populations and an extreme shortage of doctor’s and nurses. This is one of
What makes this cannabis market really exciting is that it’s largely uncharted territory. When cannabis went live last October, it opened the door for growers,
Let’s start by saying the health care system has some serious problems. It’s underfunded, understaffed and the nurses and doctors working under these circumstances should
Oxycontin, once pitched as a treatment for chronic pain, is now synonymous with the opioids currently plaguing Canada and the United States. In the U.S.
VitalHub (VHI.V) recently partnered with the Government of Yukon following the territory’s request for assistance in upgrading and streamlining its mental health and substance use medical records
by Guy Bennett Christmas Eve, 2018 – I’m writing this from a hospital bed in a hard scrabble town in the mountains of Yunnan Province,
If I was getting paid by the number of pitches I hear, I’d be making a lot more money than I do. Often, they’re terrible.
Bank breach! How come nobody cares? Privacy regs are effecting the market slowly at first, and anything that does that is usually getting ready to
A few years back, I wrote about Helius Medical Technologies (HSM.T), which I heard about from Fabrice Taylor, and liked a lot as a long
Back when it was dragging its ass along the road at $0.10 a share, we told you – again and again – that Reliq Health
For a year I talked about Reliq Health Technologies (RHT.V) being a case of not if but when. For a year I talked about RHT’s
I’ve taken a lot of crap from folks over the last year for writing positive things about medical tech firm Reliq Health Technologies (RHT.V). but
I didn’t see this coming – two Equity.Guru clients have released an MOU that they’ll jointly develop a mobile app for cannabis patients, consumers, and
Dammit, I told you so. I straight up, right here, told you Helius was going to move. And move it has, up almost every day
Am hearing unconfirmed buzz that something’s happening with Helius Medical Technologies (HSM.T) right now, and the stock is certainly indicating that might be the case.
